CatalystMarker
← board

SBFMW

distress 6/10 · elevated risk
$0.03-63%today-69% from 52w high
sunshinebiopharma.com50 employeesFort Lauderdale, FL
Revenue
pre-revenue
Liquidity
$7M
Runway
1.2 yrs
Shares 1y
+10%

Price & events

-68.3% over 6M
$0.03$0.07$0.10Mar 26May 26Jul 26200dilution: 424B5 offering (2026-07-20)dilution: 424B4 offering (2026-05-19)dilution: EFFECT shelf_effective (2026-05-18)dilution: S-1 shelf_registration (2026-05-12)financing: 8-K material_agreement (2026-07-20)financing: 8-K material_agreement (2026-07-10)financing: 8-K material_agreement (2026-05-19)
CatalystRating changeDilutionFinancingdashed = today
-63.3%
1D
-63.3%
1W
-63.3%
1M
-63.3%
3M
—
6M
—
1Y
—
2Y
—
5Y
-68.3%
All

Overview

Market Cap
$156.19K
Volume
200
52 Week Range
$0.03 – $0.10
Total Shares
5.01M
Float Shares
497.44K
RVOL
30.00x
Beta
1.31

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 5,005,945 · 3 offerings/1y · 0 PIPEs
  • 2026-07-208-Kmaterial_agreement
  • 2026-07-20424B5offering
  • 2026-07-108-Kmaterial_agreement
  • 2026-05-198-Kmaterial_agreement
  • 2026-05-19424B4offering
  • 2026-05-18EFFECTshelf_effective
  • 2026-05-12S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.